Medicine
Deferoxamine 95 mg/mL powder for injection
Deferoxamine 95 mg/mL powder for injection is a generic prescription medicine for intramuscular, intravenous, subcutaneous use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
STORE AT: 20 ºC to 25 °C ( 68 ºF to 77 °F).
Key facts
- Active ingredient (INN)
- Deferoxamine
- Brand
- Sold under the generic name
- Strength
- 95 mg/mL
- Dosage form
- Powder for injection
- Route
- Intramuscular, intravenous, subcutaneous
- Packs
- 1 vial
- Manufacturer
- Fresenius Kabi
- Origin register
- US FDA, United States
- Storage
- STORE AT: 20 ºC to 25 °C ( 68 ºF to 77 °F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V03AC01 Deferoxamine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 December 2009
- Identifiers
- RxCUI 1731345, 1731350DailyMed set ID d91e16df-8daa-4cd2-86a2-273eaa2446e0NDC 63323-597, 63323-599Application ANDA078718
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 box / 5.3 mL in 1 vial | 63323-597-10 | Fresenius Kabi | 15 December 2009 |
| 1 vial in 1 box / 21.1 mL in 1 vial | 63323-599-30 | Fresenius Kabi | 15 December 2009 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 1 April 1968 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Deferoxamine
Clinical summary
Deferoxamine is an iron chelator indicated as an adjunct to standard measures for the treatment of acute iron intoxication, among other approved uses. It is available as powder for injection for intravenous, intramuscular and subcutaneous use. MedsAcross supplies Deferoxamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DeferoxamineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Desferal prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Deferoxamine 95 mg/mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.